<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255670</url>
  </required_header>
  <id_info>
    <org_study_id>224/13/03/02/2009</org_study_id>
    <nct_id>NCT01255670</nct_id>
  </id_info>
  <brief_title>Penicillin and Metronidazole in Treatment of Peritonsillar Abscess</brief_title>
  <official_title>Penicillin and Metronidazole in Treatment of Peritonsillar Abscess - Prospective, Double-blind, Randomized, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of peritonsillar abscess varies. To study whether broad spectrum antibiotics are&#xD;
      required in addition to abscess drainage, a prospective, double blind, placebo-controlled,&#xD;
      randomized study on 200 adult patients with peritonsillar abscess is performed. 100 patients&#xD;
      are given penicillin and metronidazole and 100 patients get penicillin and placebo. Recovery&#xD;
      and recurrence are analyzed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Recurrence of Peritonsillar Abscess</measure>
    <time_frame>56 days</time_frame>
    <description>Number of participants with recurrence of peritonsillar abscess having metronidazole in addition to penicillin or penicillin and placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Recovering From Peritonsillar Abscess</measure>
    <time_frame>28 days</time_frame>
    <description>Number of participants recovering from peritonsillar abscess having metronidazole in addition to penicillin or penicillin and placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Peritonsillar Abscess</condition>
  <arm_group>
    <arm_group_label>penicillin and metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess</description>
  </arm_group>
  <arm_group>
    <arm_group_label>penicillin and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>penicillin and metronidazole in peritonsillar abscess</intervention_name>
    <description>Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days</description>
    <arm_group_label>penicillin and metronidazole</arm_group_label>
    <arm_group_label>penicillin and placebo</arm_group_label>
    <other_name>Medicillin</other_name>
    <other_name>Flagyl</other_name>
    <other_name>Tricozol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  referring doctor suspects peritonsillar abscess&#xD;
&#xD;
          -  patient is voluntary&#xD;
&#xD;
          -  patient has daily access to his/her e-mail&#xD;
&#xD;
          -  patient speaks and understands Finnish of Swedish&#xD;
&#xD;
          -  female patients have adequate birth-control method&#xD;
&#xD;
          -  patient has peritonsillar abscess&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to penicillin&#xD;
&#xD;
          -  allergy to metronidazole&#xD;
&#xD;
          -  use of metronidazole in preceding one month&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  breast-feeding&#xD;
&#xD;
          -  renal insufficiency&#xD;
&#xD;
          -  liver insufficiency&#xD;
&#xD;
          -  alcoholism (drunk at least once a week)&#xD;
&#xD;
          -  participant in another clinical trial at the moment&#xD;
&#xD;
          -  treatment of peritonsillar abscess requires in-patient care&#xD;
&#xD;
          -  tonsillectomy during the next 30 days&#xD;
&#xD;
          -  army recruit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karin V Blomgren, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>consultant</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <results_first_submitted>March 18, 2021</results_first_submitted>
  <results_first_submitted_qc>April 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2021</results_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Karin Blomgren</investigator_full_name>
    <investigator_title>Senior Medical Officer in Charge of Research</investigator_title>
  </responsible_party>
  <keyword>Peritonsillar Abscess</keyword>
  <keyword>Quinsy</keyword>
  <keyword>Penicillin</keyword>
  <keyword>Metronidazole</keyword>
  <keyword>Recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abscess</mesh_term>
    <mesh_term>Peritonsillar Abscess</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Penicillins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Penicillin and Metronidazole</title>
          <description>After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess.&#xD;
Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Penicillin and Placebo</title>
          <description>After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess.&#xD;
Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Penicillin and Metronidazole</title>
          <description>After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess.&#xD;
Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Penicillin and Placebo</title>
          <description>After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess.&#xD;
Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                    <count group_id="B2" value="100"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                    <count group_id="B2" value="100"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Finland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                    <count group_id="B2" value="100"/>
                    <count group_id="B3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Recurrence of Peritonsillar Abscess</title>
        <description>Number of participants with recurrence of peritonsillar abscess having metronidazole in addition to penicillin or penicillin and placebo.</description>
        <time_frame>56 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penicillin and Metronidazole</title>
            <description>After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess.&#xD;
Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Penicillin and Placebo</title>
            <description>After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess.&#xD;
Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrence of Peritonsillar Abscess</title>
          <description>Number of participants with recurrence of peritonsillar abscess having metronidazole in addition to penicillin or penicillin and placebo.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Mann-Whitney U-test and Fisher's exact test</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Recovering From Peritonsillar Abscess</title>
        <description>Number of participants recovering from peritonsillar abscess having metronidazole in addition to penicillin or penicillin and placebo.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penicillin and Metronidazole</title>
            <description>After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess.&#xD;
Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Penicillin and Placebo</title>
            <description>After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess.&#xD;
Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Recovering From Peritonsillar Abscess</title>
          <description>Number of participants recovering from peritonsillar abscess having metronidazole in addition to penicillin or penicillin and placebo.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mann-Whitney U-test and Fisher's exact test</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Penicillin and Metronidazole</title>
          <description>After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess.&#xD;
Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Penicillin and Placebo</title>
          <description>After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess.&#xD;
Penicillin and metronidazole in peritonsillar abscess: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days; Peroral metronidazole: 500 mg 3 times a day for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Karin Blomgren</name_or_title>
      <organization>Helsinki University Central Hospital</organization>
      <phone>+358504271579</phone>
      <email>karin.blomgren@hus.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

